Cytoprotection in the treatment of pediatric cancer: Review of current strategies in adults and their application to children

Medical and Pediatric Oncology

Volumn 32, Issue 2, 1999, Pages 124-134

  Bukowski, Ronald ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Amifostine; Cytoprotection; Cytotoxicity; Dexrazoxane; Pediatric neoplasms

Indexed keywords

AMIFOSTINE; ANTHRACYCLINE; ASPARAGINASE; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIETHYLDITHIOCARBAMIC ACID; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; PREDNISONE; RAZOXANE; TENIPOSIDE; THIOSULFATE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOMYOPATHY; CELL PROTECTION; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; GENOTOXICITY; HUMAN; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RADIATION INJURY; SECOND CANCER;

ANTINEOPLASTIC AGENTS; CHILD; CLINICAL PROTOCOLS; CYTOPROTECTION; HUMANS; NEOPLASMS; NEOPLASMS, SECOND PRIMARY;

EID: 0032918917     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199902)32:2<124::AID-MPO10>3.0.CO;2-Z     Document Type: Article

References (109)

1. Powis G. Toxicity of anticancer drugs to humans: a unique opportunity to study human toxicity. In: Powis G, Hacker MP, editors. The toxicity of anticancer drugs. New York: Pergamon Press; 1991. p 1-9.
2. Taylor RE. Cancer in children: radiotherapeutic approaches. Br Med Bull 1996;52:873-386.
3. Sorensen K, Levitt G, Sebag-Montefiore D, et al. Cardiac function in Wilms' tumor survivors. J Clin Oncol 1995;13:1546-1556.
4. Bristow MR, Thompson PD, Martin RP, et al. Early anthracycline cardiotoxicity. Am J Med 1978;65:823-832.
5. Gaudin PB, Hruban RH. Beschorner WE et al. Myocarditis associated with doxorubicin cardiotoxicity. Am J Clin Pathol 1993; 100:158-163.
6. Koning J, Palmer P, Franks CR, et al. Cardioxane - ICRF-187: towards anticancer drug specificity through selective toxicity reduction. Cancer Treat Rev 1991;18:1-19.
7. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-314.
8. Godoy LY, Fukushige J, Igarashi H, et al. Anthracycline-induced cardiotoxicity in children with malignancies. Acta Paediatr Jpn 1997;39:188-193.
9. Pratt CB, Meyer WH, Jenkins JJ, et al. Ifosfamide, Fanconi's syndrome, and rickets. J Clin Oncol 1991;9:1495-1499.
10. Segal LS, Palumbo RC, Robertson WW Jr. The development of rickets as a complication of chemotherapy for the treatment of Wilms' tumor. Orthopedics 1995;18:261-264.
11. Dentino M, Luft FC, Yum MN, et al. Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 1978;41:1274-1281.
12. Stoter G, Koopman A, Vendrik CPJ, et al. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol 1989;7:1099-1104.
13. De Santo NG, Capasso G, Capodicasa G, et al. Acute renal failure due to cisplatin. Int J Pediatr Nephrol 1986;7:145-150.
14. Gomez Campdera FJ, Gonzalez P, Carrillo A, et al. Cisplatin nephrotoxicity: symptomatic hypomagnesemia and renal failure. Int J Pediatr Nephrol 1986;7:151-152.
15. Hayes DM, Cvitkovic E, Golbey RB, et al. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977;39:1372-1381.
16. Gerritsen van der Hoop R, van der Burg MEL, ten Bokkel Huinink WW, et al. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990;66: 1697-1702.
17. Cersosimo RJ. Cisplatin neurotoxicity. Cancer Treat Rev 1989; 16:195-211.
18. Hertzberg H, Huk WJ, Ueberall MA, et al. CNS late effects after ALL therapy in childhood. Part I: neuroradiological findings in long-term survivors of childhood ALL - an evaluation of the inferences between morphology and neuropsychological performance. The German Late Effects Working Group. Med Pediatr Oncol 1997;28:387-400.
19. Levine EG Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Sen in Oncol 1992;19:47-84.
20. Smith MB, Xue H, Strong L, et al. Forty-year experience with second malignancies after treatment of childhood cancer: analysis of outcome following the development of the second malignancy. J Pediatr Surg 1993;28:1342-1348.
21. Green DM, Zevon MA, Reese PA, et al. Second malignant tumors following treatment during childhood and adolescence for cancer. Med Pediatr Oncol 1994;22:1-10.
22. Tucker MA, Meadows AT, Boice JD Jr., et al. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 1987;78:459-464.
23. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745-751.
24. Wolden SL, Lamborn KR, Cleary SF, et al. Second cancers following pediatric Hodgkin's disease. J Clin Oncol 1998;16: 536-544.
25. Rosso P, Terracini B, Fears TR, et al. Second malignant tumors after elective end of therapy for a first cancer in childhood: a multicenter study in Italy. Int J Cancer 1994;59:451-456.
26. Salvati M, Cervoni L, Artico M. High-dose radiation-induced meningiomas following acute lymphoblastic leukemia in children. Child Nerv Syst 1996;12:266-269.
27. Stein ME, Drumea K, Guilbord JN, et al. Case report: late aggressive meningioma following prophylactic cranial irradiation for acute lymphoblastic leukaemia. Br J Radiol 1995;68:1123-1225.
28. Breslow NE, Takashima JR, Whitton JA, et al. Second malignant neoplasms following treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1995;13: 1851-1859.
29. Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double-blind placebo-controlled trial. Ann Intern Med 1994;121:492-501.
30. Bergmann L, Karakas T, Knuth A, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma - a randomized pilot study. Eur J Cancer 1995;31A:2164-2168.
31. Hartmann LC, Tschetter LK, Habermann TM, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997;336:1776-1780.
32. Burdach SEG, Müschenich M, Josephs W, et al. Granulocyte-macrophage-colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors: results of a prospective randomized study. Cancer 1995; 76:510-516.
33. Lydaki E, Bolonaki E, Stiakaki E, et al. Efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte-macrophage colony-stimulating factor in neutropenic children with malignancies. Pediatr Hematol Oncol 1995;12:551-558.
34. Wexler LH, Weaver-McClure L, Steinberg SM, et al. Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. J Clin Oncol 1996;14:901-910.
35. Pui C-H, Boyett JM, Hughes WT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997; 336:1781-1787.
36. Meropol NJ, Miller LL, Korn EL, et al. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992;84:1201-1203.
37. Calderwood S, Romeyer F, Blanchette V, et al. Concurrent RhGM-CSF does not offset myelosuppression from intensive chemotherapy: randomized placebo-controlled study in childhood acute lymphoblastic leukemia. Am J Hematol 1994;47:27-32.
38. Calabro-Jones PM, Aguilera JA, Ward JF, et al. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 1988;48:3634-3640.
39. Harris JW, Phillips TL. Radiobiological and biochemical studies of thiophosphate radioprotective compounds related to cysteamine. Radiat Res 1971;46:362-379.
40. Grdina DJ, Shigematsu N, Dale P, et al. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action. Carcinogenesis 1995;16: 767-774.
41. Glover D, Glick JH, Weiler C, et al. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled Phase II trial. J Clin Oncol 1986;4:584-588.
42. Betticher DC, Anderson H, Ranson M, et al. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised Phase II study. Br J Cancer 1995;72:1551-1555.
43. Budd GT, Bukowski RM, Murthy S, et al. Randomized trial of carboplatin (CBDCA) vs. CBDCA + amifostine (AMI) in advanced malignancy [abstract]. Proc Am Soc Clin Oncol 1994;13: 442.
44. Budd GT, Bukowski RM, Adelstein D, et al. Mature results of a randomized trial of carboplatin (C) and amifostine (A) vs. C alone in patients (pts) with advanced malignancies [abstract]. Proc Am Soc Clin Oncol 1996;15:532.
45. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14:2101-2112.
46. Schiller JH, Storer B, Berlin J, et al. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 1996; 14:1913-1921.
47. Adamson PC, Balis FM, Belasco JE, et al. A Phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res 1995;55:4069-4072.
48. Borsi JD, Csáki C, Ferencz T, et al. Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin. Anti-Cancer Drugs 1996;7:121-126.
49. Borsi JD, Csáski C, Ferencz T, et al. Safety and efficacy of amifostine in children to prevent myelotoxicity of high-dose carboplatin: preliminary results of a cooperative Phase I-II clinical trial [abstract]. Proc Am Soc Clin Oncol 1997;16:523a.
50. Patchen ML, MacVittie TJ, Souza LM. Postirradiation treatment with granulocyte colony-stimulating factor and preirradiation WR-2721 administration synergize to enhance hemopoietic reconstitution and increase survival. Int J Radiat Oncol Biol Phys 1992;22:773-779.
51. Huang X-K, Gao XZ, Burke P, et al. The effects of amifostine on the clonogenic proliferation in vitro of myelodysplastic and acute and chronic myelogenous leukemia cells [abstract]. Proc Am Soc Clin Oncol 1997;16:514a.
52. List AF, Heaton R, Glinsmann-Gibson B, et al. A Phase I/II clinical trial of amifostine in patients with myelodysplastic syndrome (MDS): promotion of multilineage hematopoiesis [abstract]. Proc Am Soc Clin Oncol 1997;16:7a.
53. East CJ, Abboud CN, Borch RF. Diethyldithiocarbamate induction of cytokine release in human long-term bone marrow cultures. Blood 1992;80:1172-1177.
54. Berry JM, Jacobs C, Sikic B, et al. Modification of cisplatin toxicity with diethyldithiocarbamate. J Clin Oncol 1990;8:1585-1590.
55. Rothenberg ML, Ostchega Y, Steinberg SM, et al. High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer. J Natl Cancer Inst 1988;80:1488-1490.
56. Francis P, Markman M, Hakes T, et al. Diethyldithiocarbamate chemoprotection of carboplatin-induced hematological toxicity. J Cancer Res Clin Oncol 1993;119:360-362.
57. Gandara DR, Nahhas WA, Adelson MD, et al. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol 1995;13:490-496.
58. Iwamoto Y, Kawano T, Ishizawa M, et al. Inactivation of cis-diamminedichloroplatinum (II) in blood and protection of its toxicity by sodium thiosulfate in rabbits. Cancer Chemother Pharmacol 1985;15:228-232.
59. Howell SB, Kirmani S, Lucas WE, et al. A Phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer. J Clin Oncol 1990;8:137-145.
60. Wellner VP, Anderson ME, Puri RN, et al. Radioprotection by glutathione ester: transport of glutathione ester in human lymphoid cells and fibroblasts. Proc Natl Acad Sci USA 1984;81: 4732-4735.
61. Cozzaglio L, Doci R, Colella G, et al. A feasibility study of high-dose cisplatin and 5-fluorouracil with glutathione protection in the treatment of advanced colorectal cancer. Tumori 1990;76: 590-594.
62. Di Re F, Bohm S, Oriana S, et al. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Ann Oncol 1993;4:55-61.
63. Büntzel J, Glatzel M, Küttner K, et al. Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer [abstract]. Ann Oncol 1996;7(Suppl 5):81.
64. Constine LS, Zagars G, Rubin P, et al. Protection by WR-2721 of human bone marrow function following irradiation. Int J Radiat Oncol Biol Phys 1986;12:1505-1508.
65. Wadler S, Beitler JJ, Rubin JS. Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York gynecologic oncology group study. J Clin Oncol 1993;11:1511-1516.
66. Borgmann A, Emminger W, Emminger-Schmidmeier W, et al. Influence of fractionated total body irradiation on mucosal toxicity in intensified conditioning regimens for autologous bone marrow transplantation in pediatric cancer patients. Klin Pädiatr 1994;206:299-302.
67. Vaughan WP, Kris E, Vose J, et al. Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma. J Clin Oncol 1995;13:1089-1095.
68. Saez RA, Slease RB, Strnad C, et al. High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation for the treatment of advanced malignancies: a Phase I study. Bone Marrow Transplant 1995;16:507-514.
69. Rask C, Albertioni F, Schrøder H, et al. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate. Pediatr Hematol Oncol 1996;13:359-367.
70. Tyc VL, Vallelunga L, Mahoney S, et al. Nutritional and treatment-related characteristics of pediatric oncology patients referred or not referred for nutritional support. Med Pediatr Oncol 1995;25:379-388.
71. Erkisi M, Erkurt E, Ozharlas S, et al. The use of recombinant human granulocyte colony-stimulating factor in combination with single or fractionated doses of ifosfamide and doxorubicin in patients with advanced soft tissue sarcoma. J Chemother 1996; 8:224-228.
72. Mills W, Strang J, Goldstone AH, et al. Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. Leuk Lymphoma 1995;17:263-270.
73. Liu T, Liu Y, He S, et al. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 1992;69:2820-2825.
74. Tannehill SP, Mehta MP, Larson M, et al. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a Phase II trial. J Clin Oncol 1997;15:2850-2857.
75. Glover D, Glick JH, Weiler C, et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma J Clin Oncol 1987;5:574-578.
76. Planting AST, Vermorken JB, Catimel G, et al. Randomized phase II study of weekly cisplatin with or without amifostine in patients w th advanced head and neck cancer [abstract]. Ann Oncol 1996;7(Suppl 5):79,A374P.
77. Mollman JE, Glover DJ, Hogan WM, et al. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 1988;61:2192-2195.
78. Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomizec double-blind placebo-controlled rial. J Clin Oncol 1995;13:26-32.
79. Sumiyoshi Y, Hashine K, Kasahara K, et al. Glutathione chemoprotection therapy against CDDP-induced neurotoxicity in patients with invasive bladder cancer. Jpn J Cancer Chemother 1996;23:1536-1508.
80. Gebbia V, Valenza R, Testa A, et al. Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with glutathione protection in patients with advanced head and neck cancer. Med Oncol Tumor Pharmacother 1992;9:165-168.
81. Plaxe S, Freddo J, Kim S, et al. Phase I trial of cisplatin in combination with glutathione. Gynecol Oncol 1994;55:82-86.
82. Gandara DR, Wiebe VJ, Perez EA, et al. Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. Crit Rev Oncol Hematol 1990;10:353-365.
83. Paredes J, Hong WK, Felder TB, et al. Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 1988;6:955-962.
84. Markman M, Cleary S, Howell SB. Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection. Eur J Cancer 1985;21:1015-1018.
85. Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982;97: 845-851.
86. Kim S, Howell SB, McClay E, et al. Dose intensification of cisplatin chemotherapy through biweekly administration. Ann Oncol 1993 4:221-227.
87. Malgrange B, Delree P, Rigo JM, et al. Image analysis of neuritic regeneratior by adult rat dorsal root ganglion neurons in culture: quantification of the neurotoxicity of anticancer agents and of its prevention by nerve growth factor or basic fibroblast growth factor but not brain-derived neurotrophic factor or neurotrophin-3. J Neurosci Methods 1994;53:111-122.
88. Zheng JL, Stewart RR, Gao WQ. Neurotrophin-4/5, brain-derived neurotrophic factor, and neurotrophin-3 promote survival of cultured vestibular ganglion neurons and protect them against neurotoxicity of ototoxins. J Neurobiol 1995;28:330-340.
89. Gerritsen van der Hoop R, Vecht CJ, van der Burg MEL, et al. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 1990;322: 89-94.
90. Neijt J, van der Burg M, Vecht C, et al. A double-blind randomised study with ORG-2766 an ACTH(4-9) analog, to prevent cisplatin neuropathy [abstract]. Proc ASCO 1994;13:261,A837.
91. Roberts JA, Jenison EL, Kim K, et al. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 1997; 67:172-177.
92. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-815.
93. Sehested M, Jensen PB. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 1996;51:879-886.
94. Sehested M, Jensen PB, Sørensen BS, et al. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 1993;46:389-393.
95. Hasinoff BB. The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane). Agents Actions 1990;29:374-381.
96. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992;10:117-127.
97. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988;319:745-752.
98. ten Bokkel Huinink WW, Schreuder JE, Dubbelman R, et al. ICRF 187 protects against doxorubicin induced cardiomyopathy [abstract]. Ann Oncol 1993;3(Suppl 1):114.
99. Bu'Lock FA, Gabriel HM, Oakhill A, et al. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J 1993;70:185-188.
100. Schiavetti A, Castello MA, Versacci P, et al. Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results. Pediatr Hematol Oncol 1997;14:213-222.
101. Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996;14:362-372.
102. Rhomberg W, Hassenstein EOM, Gefeller D. Radiotherapy vs. radiotherapy and razoxane in the treatment of soft tissue sarcomas: final results of a randomized study. Int J Radiat Oncol Biol Phys 1996;36:1077-1084.
103. Lipshultz SE: Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J Clin Oncol 1996;14:328-331.
104. Bhanumathi P, Saleesh EB, Vasudevan DM. Creatinine phosphokinase and cardiotoxicity in adriamycin chemotherapy and its modification by WR-1065. Biochem Arch 1992;8:335-338.
105. Green D, Wright A, Schein P, et al. WR-2721 chemoprotection of doxorubicin toxicity in mice [abstract]. Proc Am Assoc Cancer Res 1992;33:490.
106. Dorr RT, Lagel K, McLean S. Cardioprotection of rat heart myocytes with amifostine (Ethyol®) and its free thiol, WR-1065, in vitro. Eur J Cancer 1996;32A(Suppl 4):S21-S25.
107. Pissarek M, Jänichen F, Blasig IE, et al. Cardioprotective potency of the radial scavenger S-2-(3-aminopropylamino) ethylphosphorothioic acid in the post-ischaemic rat heart. Mol Cell Biochem 1995;145:121-129.
108. Grdina DJ, Nagy B, Sigdestad CP. Radioprotectors in treatment therapy to reduce risk in secondary tumor induction. Pharmacol Ther 1988;39:21-25.
109. Stoller RG, Hande KR, Jacobs SA, et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977;297:630-634.